Search Technologies
Displaying 1 - 10 of 83 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Functional Myelination of Neurons
Published Tuesday, May 7, 2024Summary This invention is a significant advancement in regenerative medicine, offering a novel stem cell-based therapy for demyelinating diseases. It utilizes melanocyte stem cells (MeSCs) from the skin to differentiate into cells capable of myelination, addressing diseases like...
Investigator(s): Thomas Hornyak and Sandeep Joshi
Categories: Therapeutics, Biologics, Stem Cells, Methods of Treatment
Docket: TH-2015-020
-
Identification of Toll-Like Receptor 2 (TLR2) Antagonists Using Computer-Aided Drug Design
Published Wednesday, March 6, 2024Toll-like receptors (TLR) are innate immune molecules involved in the detection of microbial and self-ligands released from damaged cells. At their C-termini, toll/interleukin-1 receptor (TIR) domains dimerize upon ligand binding, initiating a signaling cascade that results in the upregulation of inflammatory cytokines. Excessive signaling can...
Investigator(s): Alexander D. MacKerell, Stefanie N. Vogel
Categories: Platforms, Therapeutics
Keyword(s): TLR2, sepsis, anti-inflammation, TIR
Docket: SV-2010-075
-
Preventing Metastatic Breast Cancer with Therapeutic Lectin
Published Monday, March 4, 2024UMB inventors led by Prof. Amy Fulton and Prof. David Weber have developed a novel recombinant protein – a lectin known as “rEMSL1” - and elucidated its structure, binding characteristics, and probable mechanism of action. The rEMSL1 construct has been optimized for expression from mammalian cell lines. In...
Investigator(s): Amy Fulton, David Weber, Raquel Godoy-Ruiz, Namita Kundu
Categories: Therapeutics
Keyword(s): Cancer; metastasis; stem cells; biologic; lectin
Docket: AF-2021-040
-
SMALL MOLECULE STAT3 INHIBITOR FOR TREATING TRIPLE NEGATIVE BREAST CANCER
Published Monday, December 11, 2023Summary The patent application describes the molecule LLL12B which targets STAT3 protein. STAT3 is pivotal in cancer progression. LLL12B is novel therapy that addresses an unmet need in TNBC and pancreatic cancer treatment. The breast cancer therapeutics market, valued at $28.8...
Investigator(s): Jiayuh Lin, Li Pan
Categories: Therapeutics, Small molecules
Keyword(s): • STAT3 Inhibitor, triple-negative breast cancer, pancreatic cancer, Targeted Cancer Therapy
Docket: JL-2022-040
-
Compositions and Methods for Delivering Nucleic Acids to Cells
Published Wednesday, December 6, 2023Summary This invention provides a breakthrough in gene therapy and molecular biology, featuring a non-viral vector system for delivering nucleic acids to cells. It utilizes a polyplex particle with acetylated polyethylenimine (Ac-PEI) and an anionic biomaterial envelope, reducing...
Investigator(s): Ryan Pearson and Atanu Chakraborty
Categories: Therapeutics, Biologics, Methods of Treatment
Docket: RP-2020-012
-
Compositions and Methods for Treating Inflammation and Cancer
Published Thursday, November 2, 2023Summary The patent "Compositions and Methods for Treating Inflammation and Cancer" introduces a novel approach to immunotherapy by modulating the LTβR-NFκB signaling pathways. This technology aims to enhance treatment specificity and efficacy for tissue rejection and certain...
Categories: Therapeutics
Docket: JB-2017-082
-
Compounds and Methods for Addressing Proteotoxicity-Associated Diseases
Published Thursday, July 27, 2023Summary The patent, "Compounds and methods for treating proteotoxicity-associated diseases", introduces a novel approach to combat proteotoxicity - a condition where misfolded or aggregated proteins become harmful...
Investigator(s): Fengtian Xue, Jiou Wang, Tao Zhang, Yu-Ning Lu
Categories: Therapeutics, Small molecules
Keyword(s): Proteotoxicity, Neurodegenerative Diseases, Protein Misfolding, Therapeutic Compounds
Docket: FX-2022-001
-
Water Proton NMR for Monitoring Sedimentation Process of Multiphase Mixtures
Published Tuesday, June 27, 2023Summary The technology developed by the University of Maryland, Baltimore utilizes water proton Nuclear Magnetic Resonance (NMR) to monitor the sedimentation process in multiphase mixtures in real-time. This analytical method...
Investigator(s): Bruce Yu, Marc Taraban
Categories: Research Tools, Antibodies, & Reagents, Therapeutics, Small molecules, Chemicals, Biologics, Vaccines
Keyword(s): Sedimentation Monitoring, Multiphase Mixtures, Water Proton NMR, Pharmaceutical, Specialty Chemical, Specialty Materials
Docket: BY-2020-149
-
Muscarinic Antagonists for the Treatment of Depression
Published Monday, June 26, 2023Summary The disclosed technology describes the utilization of muscarinic antagonists for the treatment of depression. Muscarinic antagonists are a class of compounds that block muscarinic acetylcholine receptors to ameliorate...
Investigator(s): Andrew Coop, Jack Bergman, Chad Johnson, Brian Kangas, James Woods, Emily Jukiewicz, Gail Winger
Categories: Therapeutics, Small molecules, Methods of Treatment
Keyword(s): depression, Muscarinic Antagonists, Mood Regulation
Docket: AC-2019-107
-
Dual Wnt Signaling Pathway Inhibitors and AMPK Activators for Treatments of Disease
Published Wednesday, May 24, 2023Summary The technology presents a novel approach to treating diseases such as various types of cancer and metabolic diseases. Disclosed is a series of compounds that simultaneously inhibit the Wnt/beta-catenin pathway and...
Investigator(s): Fengtian Xue, Yan Shu, Yong Al
Categories: Therapeutics, Small molecules
Keyword(s): Wnt Signaling inhibitor, AMPK activators, cancer, Metabolic Disease, Therapeutic
Docket: FX-2021-051